Paul W. Sperduto
Expertise in
18
conditions

Dr. Paul W. Sperduto

Radiation Oncology
490 S Maple St, # 117, 
Waconia, MN 
Expertise in
18
conditions
490 S Maple St, # 117, 
Waconia, MN 

Overview

Paul Sperduto is a Radiation Oncologist practicing medicine in Waconia, Minnesota.

Dr. Sperduto is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Posterior Fossa Tumor, Brain Tumor, Prostatectomy, and Gamma Knife Radiosurgery.

He is actively involved in clinical research, co-authoring 64 peer reviewed articles and participating in 20 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in MN

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
HealthPartners
  • POS
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medica
  • EPO
  • HMO
  • PPO

Locations

490 S Maple St, # 117, Waconia, MN 55387

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
Enrollment Status: Active_not_recruiting
Publish Date: August 27, 2026
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 3
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin
Enrollment Status: Completed
Publish Date: August 27, 2026
Intervention Type: Other, Biological, Radiation
Study Drugs: Cetuximab, Durvalumab
Study Phase: Phase 2/Phase 3
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Drug, Procedure, Radiation, Other
Study Drugs: Carboplatin, Paclitaxel, FOLFOX regimen, CAPOX regimen, Docetaxel, 5FU
Study Phase: Phase 3
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging Into Salvage Treatment for Patients With Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying Treatment for NOde Positive Prostate Cancer by VArying the Hormonal ThErapy
Enrollment Status: Active_not_recruiting
Publish Date: August 17, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Abiraterone acetate, Apalutamide, Hormone therapy, Prednisone
Study Phase: Phase 3
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
A Phase IIR/III Trial of Standard of Care Therapy With or Without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer
Enrollment Status: Completed
Publish Date: July 10, 2026
Intervention Type: Radiation, Procedure
Study Phase: Phase 2/Phase 3
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Enrollment Status: Completed
Publish Date: June 25, 2026
Intervention Type: Radiation
Study Phase: Phase 1
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel
Enrollment Status: Completed
Publish Date: June 25, 2026
Intervention Type: Drug, Other, Radiation
Study Drugs: Bicalutamide, Docetaxel, Flutamide, Goserelin acetate, Leuprolide acetate, Nilutamide
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

64 Total Publications

Broadening clinical trial inclusivity of patients with lung cancer and brain metastases utilizing the Graded Prognostic Assessment (GPA): A call to action.
Broadening clinical trial inclusivity of patients with lung cancer and brain metastases utilizing the Graded Prognostic Assessment (GPA): A call to action.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: February 02, 2026
Similar Doctors
Expertise in
23
conditions
Dr. Darcy R. Mcbride
Radiation Oncology
Expertise in
23
conditions
Dr. Darcy R. Mcbride
Radiation Oncology
Referral may be required

Minneapolis Radiation Oncology PA

7401 Metro Blvd Ste 210, 
Edina, MN 
 (20.5 miles away)
952-920-4915
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Darcy Mcbride is a Radiation Oncologist practicing medicine in Edina, Minnesota. Dr. Mcbride is highly rated in 23 conditions, according to our data. His clinical expertise encompasses Pleuropulmonary Blastoma, Lung Cancer, Breast Cancer, and Follicular Lymphoma. Dr. Mcbride is currently accepting new patients.

Expertise in
17
conditions
Dr. Elizabeth H. Cameron
Radiation Oncology
Expertise in
17
conditions
Dr. Elizabeth H. Cameron
Radiation Oncology
Referral may be required
420 Delaware St Se, Mmc 494, 
Minneapolis, MN 
 (28.7 miles away)
612-273-8383
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Elizabeth Cameron is a Radiation Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Cameron is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Pleuropulmonary Blastoma, Plasmacytoma, Posterior Fossa Tumor, and Primitive Neuroectodermal Tumor (PNET). Dr. Cameron is currently accepting new patients.

Expertise in
9
conditions
Dr. Alexandra A. Diaz
Radiation Oncology
Expertise in
9
conditions
Dr. Alexandra A. Diaz
Radiation Oncology
Referral may be required

M Health Fairview UMMC Radiation Oncology

500 Harvard Street SE University Of Minnesota Medical Center, 1st, Floor, 
Minneapolis, MN 
 (28.7 miles away)
612-273-6700
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Alexandra Diaz is a Radiation Oncologist practicing medicine in Minneapolis, Minnesota. Dr. Diaz is highly rated in 9 conditions, according to our data. Her clinical expertise encompasses Anal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, and Familial Pancreatic Cancer. Dr. Diaz is board certified in Radiation Oncology: American Board Of Radiology, 2016. Dr. Diaz is currently accepting new patients.

Frequently Asked Questions about Dr. Paul W. Sperduto

How do I make an appointment with Dr. Paul W. Sperduto?

You can book an appointment with Dr. Paul W. Sperduto by calling their office at 952-442-6000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Paul W. Sperduto a top-rated expert for Lung Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Paul W. Sperduto is classified as an Distinguished expert for Lung Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Paul W. Sperduto specialize in?

While Dr. Paul W. Sperduto is a Radiation Oncology, they have specific expertise in Lung Cancer, Posterior Fossa Tumor, and Brain Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. Paul W. Sperduto participate in research or clinical trials?

Yes. Dr. Paul W. Sperduto has published 64 articles and abstracts on conditions like Lung Cancer. You can view a list of Dr. Paul W. Sperduto's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Paul W. Sperduto accept my insurance?

Dr. Paul W. Sperduto accepts most major insurance plans, including Blue Shield of California and HealthPartners. We recommend calling the office directly at 952-442-6000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sperduto's expertise for a condition
ConditionClose
    View All 13 Advanced Conditions
    View All 50 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile